title: [Not Available].
abstract: The HIV protease inhibitor lopinavir presents a wide inter-individual variability related to liver and intestinal metabolism involving CYP3A. Published studies were analyzed to establish whether there is evidence that therapeutic drug monitoring of lopinavir could improve patient care. In naïve or pretreated HIV-infected patients, no relationship could be evidenced between virological efficacy and trough lopinavir concentration, most likely because concentrations are above inhibitory concentrations. Although data are limited, patients with elevated triglycerides and cholesterol had trough lopinavir concentrations >8000 ng/mL. These data suggest that the level of evidence of interest of lopinavir therapeutic drug monitoring is may be recommended in some situations such as children, pregnant women, pretreated patients if the number of mutations is <5, when coadministration with drug with metabolizing enzyme inducing properties is warranted and toxicity.
authors.affiliation: Pharmacie Clinique CHU de Bicêtre, AP-HP, Le Kremlin Bicêtre, France. Electronic address: aurelie.barrail-tran@bct.aphp.fr.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Barrail-Tran
authors.affiliation: Pharmacie Clinique CHU de Bicêtre, AP-HP, Le Kremlin Bicêtre, France.
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Taburet
authors.affiliation: Pharmacologie Saint Antoine, AP-HP, Paris, France.
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Poirier
keywords: level of evidence; lopinavir; niveau de preuve; suivi thérapeutique pharmacologique; therapeutic drug monitoring